Press Releases

LUND, Sweden, May 3, 2024 /PRNewswire/ -- Hansa Biopharma AB (publ), ("Hansa" or the "Company") (STO: HNSA) today announced that the company's registered share capital and number of shares and votes have increased through the issue of 10,474,740 new ordinary shares on 12 April 2024, whereby the number of votes increased with 10,474,740 and the share capital increased with SEK 10,474,740.

As of today, the total number of registered shares of the company amounts to... (continue reading...)

STOCKHOLM, SWEDEN / ACCESSWIRE / May 3, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 3 2024- Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for first quarter 2024.

Important events during the first quarter

• In January, Vicore announced discontinuation of the preclinical IMiD program to focus resources on advancing buloxibutid... (continue reading...)

Release                                                                                 Paris, May 3rd 2024

Good business dynamics

KEY FIGURES Q1-2024:

• Total revenue1 of 12.3 billion euros, up 5.2%
• Net inflows of +1,0 billion euros
• Property & casualty portfolio growth of 3.4% year-on-year

“In the 1st quarter, Crédit Agricole Assurances achieved good results in France and abroad, driven by a growth dynamic in... (continue reading...)

Coca-Cola Europacific Partners (CCEP) today announces the resignation of Nik Jhangiani, SVP and Chief Financial Officer (CFO) with a search for his successor well underway

UXBRIDGE, UK / ACCESSWIRE / May 3, 2024 / Nik Jhangiani, CFO, has informed the Company of his intention to join Diageo plc as CFO later this year. CCEP expects to make an announcement about his successor in the near future, following a thorough search with strong candidates already identified. Nik... (continue reading...)

ANGLE commissioned to develop a Parsortix-based Androgen Receptor detection assay for use in prostate cancer studies

GUILDFORD, SURREY / ACCESSWIRE / May 3, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is delighted to announce that it has signed a supplier agreement to develop a Parsortix-based Androgen Receptor1 (AR)... (continue reading...)